Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II reduced-intensity conditioning with clofarabine + IV busulfan + ATG before allogeneic transplant in high-risk MDS/AML/ALL
2008-004884-20Phase 2Active
- Sponsor
- CHU de Nantes
- Start
- Oct 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine, busulfan and antithymocyte globulin rabbit in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by CHU de Nantes. Primary endpoint: Relapse-free survival at 1 year. Started Oct 2008; status: active.
02
Drugs
clofarabinebusulfanantithymocyte globulin rabbit
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2008-004884-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004884-20.